Histamine dihydrochloride is under clinical development by AgoneX Biopharmaceuticals and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Histamine dihydrochloride’s likelihood of approval (LoA) and phase transition for Autism took place on 18 Mar 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Histamine dihydrochloride Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Histamine dihydrochloride overview

Histamine dihydrochloride is under development of the treatment of migraine prophylaxis, treatment of Parkinson's disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis, attention deficit hyperactivity disorder (ADHD), chronic traumatic encephalopathy, schizophrenia, epilepsy and autism. The drug candidate is administered subcutaneously. The drug candidate is a salt of histamine. It acts by targeting histamine receptor.

It was also under development for the treatment of Alzheimer's disease and addiction.

AgoneX Biopharmaceuticals overview

AgoneX Biopharmaceuticals is a clinical stage biotechnology and healthcare company that develops and commercializes pharmaceutical products. The company develops drugs for the treatment and prevention of migraine headaches, Parkinson’s disease, Alzheimer’s disease, autism and other indications. It provides pipeline portfolio such as products for various indications such as epilepsy, schizophrenia, multiple sclerosis and amyotrophic lateral sclerosis, among others. The company also develops histamine dihydrochloride, a product which helps to treat various indications. AgoneX Biopharmaceuticals is headquartered in Santa Monica, California, the US.

Quick View Histamine dihydrochloride LOA Data

Report Segments
  • Innovator
Drug Name
  • Histamine dihydrochloride
Administration Pathway
  • Subcutaneous
Therapeutic Areas
  • Central Nervous System
Key Developers
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.